Biospectra
Biospectra, Inc., headquartered in the United States, is a leading provider of high-quality raw materials for the biopharmaceutical industry. Founded in 2001, the company has established itself as a key player in the production of cell culture media, excipients, and custom manufacturing solutions, catering to the needs of biotechnology and pharmaceutical companies worldwide. With a strong focus on quality and compliance, Biospectra's core products are distinguished by their rigorous testing and validation processes, ensuring they meet the stringent requirements of regulatory bodies. The company operates primarily in the US, with significant reach in global markets, positioning itself as a trusted partner in the development of innovative therapies. Notable achievements include a commitment to sustainability and continuous improvement, reinforcing its reputation as a reliable source of biopharmaceutical materials.
DitchCarbon Score
How does Biospectra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biospectra's score of 37 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biospectra's reported carbon emissions
In 2024, Biospectra, Inc. reported total carbon emissions of approximately 7,878,000 kg CO2e, comprising 4,734,000 kg CO2e from Scope 1, 1,313,000 kg CO2e from Scope 2, and 1,524,000 kg CO2e from Scope 3 emissions. This marks a significant increase from 2023, when the company emitted about 3,072,000 kg CO2e, with Scope 1 emissions at 171,000 kg CO2e, Scope 2 emissions at 1,212,000 kg CO2e, and Scope 3 emissions at approximately 1,609,728 kg CO2e. Biospectra has set ambitious reduction targets, committing to a 42% reduction in Scope 1 and Scope 2 emissions by 2030, using 2022 as the base year. This target aligns with the Paris Agreement and has been validated through the Science Based Targets initiative (SBTi). The company aims to measure and reduce its Scope 3 emissions as part of its sustainability strategy. These commitments reflect Biospectra's dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector, positioning itself as a responsible corporate citizen in the United States.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 171,000 | 0,000,000 |
| Scope 2 | 1,212,000 | 0,000,000 |
| Scope 3 | 1,609,728 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biospectra is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
